RGCC Unveils Revolutionary Cancer Detection Test, Onco-D-clare
Posted: 8th April 2024
Categories: RGCC news
RGCC announces the launch of Onco-D-clare, a groundbreaking cancer detection test that marks a significant milestone in early cancer screening. Utilizing the cutting-edge technology of molecular biology coupled with artificial neural networks, this innovative test empowers individuals to detect cancer before symptoms manifest. Onco-D-clare operates by isolating peripheral blood mononuclear cells from blood samples, followed […]
We are delighted to announce that RGCC has received prestigious recognition as one of the top 10 Swiss Biotech companies in 2023 by Life Sciences Review. Proudly standing alongside Switzerland’s esteemed biotech leaders, this acknowledgment underscores our unwavering commitment to innovation, excellence, and our continual contribution to the life sciences sector. It also reflects our […]
SOTs effective at treating cancer in 77% of patients
Posted: 9th March 2022
Categories: RGCC news
Cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases, RGCC scientists have found. A new paper published in the in vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own or in tandem with other therapies. Supportive oligonucleotide therapy is an advanced, […]
Mutated BRCA genes raise prostate and pancreatic cancer risk
Posted: 28th February 2022
Categories: Industry news, RGCC news
Mutations in BRCA1 and BRCA2 genes increase the risk of breast cancer but may also cause prostate and pancreatic cancers in men, Cambridge University scientists have discovered. After studying the medical history of thousands of families, the team found that 27% of men who carry a BRCA 2 mutation will develop prostate cancer, and those […]
Scientists worldwide are doing incredible things to improve the diagnosis and treatment of all forms of cancer. New approaches such as targeted immunotherapies are opening up new avenues for cancer treatment that prove highly effective. At RGCC, we’ve pioneered the use of personalised genetic testing for cancer diagnosis, and others are listening with the NHS […]
We are delighted to announce the launch of a brand-new branch office dedicated to serving the needs of RGCC Network doctors in North America. RGCC International – North America has been launched in response to a period of sustained and exponential growth in this region. The team will continue to deliver excellent customer service to […]
New breast cancer therapy a step closer to clinical trials
Posted: 23rd July 2021
Categories: Industry news, RGCC news
An advanced cancer therapy developed by RGCC scientists has been categorised as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA). Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Due to enter clinical trials […]
Activating p53 protein improves cancer-killing potential
Posted: 21st July 2021
Categories: Industry news, RGCC news
Activating protein p53 can boost a patient’s immune response against cancerous tumours, researchers at Sweden’s Karolinska Institutet have discovered. Using a commercially available substance known as ALRN-6924, the team successfully generated an anti-tumour immune response. The finding improves our understanding of the crucial role p53 plays in tumour development. In the future, it could help […]
RGCC scientists develop novel new approach to inhibiting SARS-COV-2 replication
Posted: 23rd June 2021
Categories: Industry news, RGCC news
RGCC researchers have developed a new approach to tackling COVID-19 (SARS-CoV-2) that could form the basis of a new treatment option. Laboratory tests have established that the new treatments were effective at inhibiting the spread of the disease. The next stage will see them progress to develop a drug delivery system, a further step before […]
New Genistein capsule offers improved cancer-killing properties
Posted: 10th May 2021
Categories: Industry news, RGCC news
RGCC scientists have developed a new anti-cancer dietary supplement that’s 34% more effective than the leading brand. Led by RGCC’s Dr Ioannis Papasotiriou, the new product offers yet more evidence of the potential for dietary supplements in the battle against cancer. It also demonstrates RGCC’s cutting-edge research and discovery capabilities. Genistein is a naturally occurring […]
Personalised cancer vaccine 45% effective at targeting tumours
Posted: 29th April 2021
Categories: Industry news, RGCC news
Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour response. The findings provide more […]
RGCC Investigates Potential Treatments and Tests for COVID-19
Posted: 7th May 2020
Categories: Industry news, RGCC news
As the world tries to cope with the rise in cases of covid-19 during the coronavirus pandemic, drug companies are racing to develop treatments that could reduce the number of deaths from the illness. This includes the specialist medical genetic testing company RGCC, which has turned its expertise and technology in the diagnosis and treatment […]
